Oruka Therapeutics, Inc.

Oruka Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics focused on inflammatory and immunology indications, particularly psoriasis. The company's pipeline centers on three lead candidates: ORKA-001, which targets the p19 subunit of interleukin-23 and is in Phase 1 trials for psoriasis treatment; ORKA-002, targeting interleukin-17A and interleukin-17F for psoriasis, psoriatic arthritis, and related conditions; and ORKA-003, directed at an undisclosed pathway. The company is also developing ORKA-021, a sequential combination regimen pairing ORKA-002 and ORKA-001.

As a pre-revenue clinical-stage entity, Oruka Therapeutics does not currently generate product revenues. The company operates with a lean workforce of 28 full-time employees and is headquartered in Menlo Park, California. Operations are concentrated in the United States, with research and development activities focused on advancing its monoclonal antibody candidates through clinical development.